Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma

Karla Hahn; Javier F. Magrina; Byron J. Masterson

doi:10.1016/0020-7292(85)90077-3

Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma

Karla Hahn, Javier F. Magrina, Byron J. Masterson

Medical and Surgical Gynecology

Research output: Contribution to journal › Article › peer-review

Abstract

A review of 18 patients with Stage III epithelial ovarian carcinoma treated by surgery and followed by cyclophosphamide and cisplatinum combination chemotherapy is presented. At the end of 12 months from the initiation of chemotherapy, 88.9% of the patients were alive and 77.8% remained free of tumor progression. At the end of 2 years 77.8% of the patients were alive and 44.4% of the patients were free of tumor progression. The combination of cyclophosphamide and cisplatinum has low toxicity, a simple pattern of administration, and has provided satisfactory results.

Original language	English (US)
Pages (from-to)	509-513
Number of pages	5
Journal	International Journal of Gynecology and Obstetrics
Volume	23
Issue number	6
DOIs	https://doi.org/10.1016/0020-7292(85)90077-3
State	Published - Dec 1985

Keywords

Chemotherapy
Cyclophosphamide and cisplatinum combination
Epethelial ovarian carcinoma
Free tumor progression
Low toxicity
Simple pattern of administration

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1016/0020-7292(85)90077-3

Cite this

@article{6188fdafb6f6420aa62ec46343942d29,

title = "Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma",

abstract = "A review of 18 patients with Stage III epithelial ovarian carcinoma treated by surgery and followed by cyclophosphamide and cisplatinum combination chemotherapy is presented. At the end of 12 months from the initiation of chemotherapy, 88.9% of the patients were alive and 77.8% remained free of tumor progression. At the end of 2 years 77.8% of the patients were alive and 44.4% of the patients were free of tumor progression. The combination of cyclophosphamide and cisplatinum has low toxicity, a simple pattern of administration, and has provided satisfactory results.",

keywords = "Chemotherapy, Cyclophosphamide and cisplatinum combination, Epethelial ovarian carcinoma, Free tumor progression, Low toxicity, Simple pattern of administration",

author = "Karla Hahn and Magrina, {Javier F.} and Masterson, {Byron J.}",

year = "1985",

month = dec,

doi = "10.1016/0020-7292(85)90077-3",

language = "English (US)",

volume = "23",

pages = "509--513",

journal = "International Journal of Gynecology and Obstetrics",

issn = "0020-7292",

publisher = "Elsevier Ireland Ltd",

number = "6",

}

TY - JOUR

T1 - Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma

AU - Hahn, Karla

AU - Magrina, Javier F.

AU - Masterson, Byron J.

PY - 1985/12

Y1 - 1985/12

N2 - A review of 18 patients with Stage III epithelial ovarian carcinoma treated by surgery and followed by cyclophosphamide and cisplatinum combination chemotherapy is presented. At the end of 12 months from the initiation of chemotherapy, 88.9% of the patients were alive and 77.8% remained free of tumor progression. At the end of 2 years 77.8% of the patients were alive and 44.4% of the patients were free of tumor progression. The combination of cyclophosphamide and cisplatinum has low toxicity, a simple pattern of administration, and has provided satisfactory results.

AB - A review of 18 patients with Stage III epithelial ovarian carcinoma treated by surgery and followed by cyclophosphamide and cisplatinum combination chemotherapy is presented. At the end of 12 months from the initiation of chemotherapy, 88.9% of the patients were alive and 77.8% remained free of tumor progression. At the end of 2 years 77.8% of the patients were alive and 44.4% of the patients were free of tumor progression. The combination of cyclophosphamide and cisplatinum has low toxicity, a simple pattern of administration, and has provided satisfactory results.

KW - Chemotherapy

KW - Cyclophosphamide and cisplatinum combination

KW - Epethelial ovarian carcinoma

KW - Free tumor progression

KW - Low toxicity

KW - Simple pattern of administration

UR - http://www.scopus.com/inward/record.url?scp=0022383253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022383253&partnerID=8YFLogxK

U2 - 10.1016/0020-7292(85)90077-3

DO - 10.1016/0020-7292(85)90077-3

M3 - Article

C2 - 2868947

AN - SCOPUS:0022383253

SN - 0020-7292

VL - 23

SP - 509

EP - 513

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

IS - 6

ER -

Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this